Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Petros Pharmaceuticals, Inc.PTPI · Entity 8730 | Director · 10% owner | December 22, 2021 | January 03, 2022 |
| WRAP TECHNOLOGIES, INC.WRAP · Entity 6770 | Director | October 01, 2026 | October 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Petros Pharmaceuticals, Inc.
Report date December 22, 2021 · Filed January 03, 2022
Jointly reported with JCP III SM AIV, L.P., METP Holdings LLC, Juggernaut Partners III GP, L.P., Juggernaut Partners III GP, Ltd.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 5,703,544 |
Reported balance
After 2021-12-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-12-22 · Purchase · Acquired 145,773 · Balance 5,703,544 F1: See Note (1) in Exhibit 99.1. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2026-12-28 | IndirectSee Footnote | 109,329 |
Reported balance
After 2021-12-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-22 · Purchase · Acquired 109,329 · Balance 109,329 F1: See Note (1) in Exhibit 99.1. |
Filing footnotes · ownership attribution and instrument terms
F1: See Note (1) in Exhibit 99.1.
WRAP TECHNOLOGIES, INC.
Report date October 01, 2026 · Filed October 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 220,191 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 21,154 · Balance 220,191 F1: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 13,750 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. |
| Common StockSEC Table I · non-derivative | IndirectBy Juggernaut Management, LLC | 250,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 250,000 F2: The reported securities are directly owned by Juggernaut Management, LLC ("Juggernaut") and may be deemed to be beneficially owned by the Reporting Person as Manager of Juggernaut. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 13,750 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches.
F2: The reported securities are directly owned by Juggernaut Management, LLC ("Juggernaut") and may be deemed to be beneficially owned by the Reporting Person as Manager of Juggernaut. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 10, 2026 01:30 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 21,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-046650 · ownership.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,191 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 13,750 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. Read SEC document |
| July 08, 2026 Filed Jul 9, 2026 23:04 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | PurchaseCommon Stock | 100,000 | $1.10 | $110,000.00 |
DisclosureSEC source: 0001493152-26-032738 · ownership.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,037 Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:14 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantStock Option (Right to Buy) · Derivative | 34,998 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001493152-26-032215 · ownership.xml · derivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,998 Underlying: Common Stock · 34,998 shares Expires 2036-07-01 Read SEC document |
| April 01, 2026 Filed May 4, 2026 21:00 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 19,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-021130 · ownership.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,037 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 12,768 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 02:45 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantWarrants · Derivative | 250,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001493152-26-004976 · ownership.xml · derivative · entry 3 SHULMAN JOHN D · CIK 0001208886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Juggernaut Management, LLC Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-02-03 F3 · derivative.exercise_price: The warrants (the "PIPE Warrants") were purchased by the Reporting Person from the Issuer in a private placement pursuant to the Purchase Agreement. The exercise price of the PIPE Warrants is subject to adjustment in the event of any issuances of Common Stock of the Issuer or securities convertible, exercisable or exchangeable for Common Stock, at a price below $2.30. F2 · ownership.nature: The reported securities are directly owned by Juggernaut Management, LLC ("Juggernaut") and may be deemed to be beneficially owned by the Reporting Person as Manager of Juggernaut. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 02:45 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 250,000 | $2.00 | $500,000.00 |
DisclosureSEC source: 0001493152-26-004976 · ownership.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Juggernaut Management, LLC Disclosed balance after: 250,000 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.0001 per share (the "common Stock"), purchased by the Reporting Person from the Issuer in a private placement pursuant to that certain Securities Purchase Agreement, dated as of February 2, 2026, by and among the Issuer and the investors signatory thereto (the "Purchase Agreement"). F2 · ownership.nature: The reported securities are directly owned by Juggernaut Management, LLC ("Juggernaut") and may be deemed to be beneficially owned by the Reporting Person as Manager of Juggernaut. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 01, 2026 Filed Jan 6, 2026 00:46 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 9,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-000470 · ownership.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,394 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 6,106 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. Read SEC document |
| October 25, 2025 Filed Dec 30, 2025 02:13 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001493152-25-029476 · ownership.xml · derivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-10-25 F1 · derivative.exercise_date: The stock options will vest over two years with 50% vesting on the one year anniversary of the date of grant and the remaining 50% vesting equally at the end of each quarter over the following year, provided that the Reporting Person is employed or providing services to the Issuer on the applicable vesting date. Read SEC document |
| December 22, 2021 Filed Jan 3, 2022 06:13 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | PurchaseWarrant · Derivative | 109,329 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001104659-22-000036 · tm2136682-1_4seq1.xml · derivative · entry 2 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 109,329 Underlying: Common Stock · 109,329 shares Expires 2026-12-28 F1 · ownership.nature: See Note (1) in Exhibit 99.1. Read SEC document |
| December 22, 2021 Filed Jan 3, 2022 06:13 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | PurchaseCommon Stock, par value $0.0001 per share | 145,773 | $3.43 | $500,001.39 |
DisclosureSEC source: 0001104659-22-000036 · tm2136682-1_4seq1.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,703,544 F1 · balance_after: See Note (1) in Exhibit 99.1. F1 · ownership.nature: See Note (1) in Exhibit 99.1. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 14:49 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | PurchaseWarrant · Derivative | 375,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001104659-21-144901 · tm2134252-1_4.xml · derivative · entry 2 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2026-12-02 F1 · ownership.nature: See Note (1) in Exhibit 99.1. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 14:49 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | PurchaseCommon Stock, par value $0.0001 per share | 500,000 | $3.00 | $1,500,000.00 |
DisclosureSEC source: 0001104659-21-144901 · tm2134252-1_4.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,557,771 F1 · balance_after: See Note (1) in Exhibit 99.1. F1 · ownership.nature: See Note (1) in Exhibit 99.1. Read SEC document |
| October 18, 2021 Filed Oct 21, 2021 08:47 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | PurchaseWarrant · Derivative | 1,661,807 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001567619-21-018515 · doc1.xml · derivative · entry 2 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,661,807 Underlying: Common Stock · 1,661,807 shares Expires 2026-10-18 F1 · ownership.nature: See Note (1) in Exhibit 99.1. Read SEC document |
| October 18, 2021 Filed Oct 21, 2021 08:47 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | PurchaseCommon Stock, par value $0.0001 per share | 1,661,807 | $1.72 | $2,849,999.01 |
DisclosureSEC source: 0001567619-21-018515 · doc1.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,057,771 F1 · balance_after: See Note (1) in Exhibit 99.1. F2 · balance_after: Includes 185,414 shares of Common Stock previously held of record by Metuchen Therapeutics, LLC ("MT") that were received by JCP III SM AIV, L.P. as a liquidating distribution. In prior reports, the reporting persons beneficially owned the 185,414 previously held by MT. F1 · ownership.nature: See Note (1) in Exhibit 99.1. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:16 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001567619-21-007863 · doc1.xml · derivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-08 F1 · derivative.exercise_date: The shares of common stock underlying the options vested 25% on the date of grant, 25% shall vest upon the six-month anniversary of the date of grant and the remainder shall vest in equal installments over the following four fiscal quarters. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:57 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantCommon Stock, par value $0.0001 per share | 3,382,416 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-020630 · doc1.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,382,416 F1 · price: See Note (1) in Exhibit 99.1. F2 · ownership.nature: See Note (2) in Exhibit 99.1. Read SEC document |
| December 01, 2020 Filed Dec 28, 2020 19:46 UTC Amendment | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantCommon Stock, par value $0.0001 per share | 3,395,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-021618 · doc1.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner Metuchen Therapeutics, LLC · CIK 0001836798 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,395,964 F1 · shares: This amended Form 4 is being filed to add Reporting Persons and to adjust the number of securities acquired to account for the same. F2 · price: See Note (1) in Exhibit 99.1. F3 · ownership.nature: See Note (2) in Exhibit 99.1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.